Evidence map›Paper›PMID 35756747›Full record

ArticleClinical kidney journal2022

Risk of outcomes in a Spanish population with chronic kidney disease.

Roberto Alcázar, Carlos Escobar, Beatriz Palacios, Unai Aranda, Luis Varela, Margarita Capel, Antoni Sicras, Aram Sicras, Antonio Hormigo, Nicolás Manito and 1 more

Open access · goldAbstract read
In one paragraph

Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Roberto AlcázarUniversity Hospital Infanta Leonor, Madrid, Spain.
Carlos EscobarUniversity Hospital La Paz, Madrid, Spain.ORCID https://orcid.org/0000-0001-5584-4735
Beatriz PalaciosAstraZeneca, Madrid, Spain.
Unai ArandaAstraZeneca, Madrid, Spain.
Luis VarelaAstraZeneca, Madrid, Spain.
Margarita CapelAstraZeneca, Madrid, Spain.
Antoni SicrasHealth Economics and Outcomes Research, Atrys Health, Barcelona, Spain.
Aram SicrasHealth Economics and Outcomes Research, Atrys Health, Barcelona, Spain.
Antonio HormigoPrimary Care Center Salud Puerta Blanca, Malaga, Spain.
Nicolás ManitoHospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain.
Manuel BotanaHospital Universitario Lucus Augusti, Lugo, Spain.
AstraZeneca (Spain) · ESBellvitge University Hospital · ESHospital Universitario Infanta Leonor · ESHospital Universitario La Paz · ESHospital Universitario Lucus Augusti · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To assess mortality and cardiovascular and renal outcomes among patients with chronic kidney disease (CKD) (primary objective), with a particular focus on heart failure (HF) risk following diagnosis of CKD (secondary objective) in Spain. Methods: We conducted an observational study comprising cross-sectional and longitudinal retrospective analyses using secondary data from electronic health records. For the primary objective, adults with prevalent CKD [estimated glomerular filtration rate (eGFR) <60 or ≥60 mL/min/1.73 m Results: In the prevalent population, 46 786 patients with CKD without HF [75.8 ± 14.4 years, eGFR 51.4 ± 10.1 mL/min/1.73 m Conclusions: The presence of HF among CKD patients markedly increases the risk of outcomes. CKD patients have a high risk of HF, which could be partially related to insufficient treatment.

Indexed as

cardiovascularchronic kidney diseasedeathrenalSGLT2 inhibitors

Identifiers

PMID35756747
PMCPMC9217652
OpenAlexW4214634032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.